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INTRODUCTION
Breast cancer (BC) is the main cause of women’s death 
from cancer [1]. After radical treatment of patients with 
BC some of them have relapses and metastases. According 
to the theories their appearance is associated with cancer 
stem cells (CSC) — small population of stem cells which 
is the cause of growth of tumour [2] and resistance to ra-
diation therapy [3] and chemotherapy [4].
The majority of current investigations have identified 
a subpopulation of BC stem cells through surface-cell mark-
ers — CD44 and CD24 [5, 6]. One of the most investigat-
ed CSC is the phenotype CD44+/CD24–, but its clinical 
significance remains controversial. This phenotype is asso-
ciated with more aggressive clinical and pathological data 
of BC [7], it is more common in patients with distant metas-
tasis [8, 9] and it has a link with three-negative [10] and bas-
al type of tumour [11, 12]. The correlation of immunophe-
notype CD44+/CD24– with resistance to anthracyclines is 
emphasized in some researches [13, 14], but the main mech-
anisms are still unknown. Investigations to find CSC mark-
ers predicting drug resistance continue nowadays.
CD24 expression was detected in various types of car-
cinoma while it is seldom expressed in normal tissues [15]. 
Some research reports indicate that low CD24 expression 
is a characteristic biomarker, which promotes the initia-
tion and progression of tumour process [16], as well as 
demonstrates the resistance to doxorubicin [13]. The oth-
er ones show that high CD24+ expression is considered 
to be an unfavorable prognostic factor of BC, associated 
with short-term disease-free survival (DFS) and may be 
a marker of sensitivity to adjuvant chemotherapy [17, 18]. 
Besides CD24 expression was significantly correlated with 
the aggressive HER2-positive status of BC [19] and with 
drug resistance in the HER2/neu expression [20].
CD44 is a well-known transmembrane glycoprotein. It 
is a contributing factor to carcinogenesis and a progression 
to a variety of neoplasms [21]. Previous investigations have 
demonstrated that aberrant expression of CD44 is associated 
with invasion, metastasis and has a negative effect on DFS in 
patients with HER2 expression or a basal-like BC [21]. But 
Horiguchi [22] substantiated that DFS is higher with high 
expression of CD44. At the same time, the other authors 
do not observe any differences in clinical outcomes and sur-
vival in regards to the expression of CD44 and CD24 [19].
Thus, numerous investigations about the role of CD44, 
CD24 in carcinogenesis and contradictory data of their prog-
nostic significance have determined our interest for further 
research. In addition, the predictive potential of these bio-
markers has not been sufficiently studied. Therefore, our task 
is to evaluate prognostic and predictive value of biomarkers 
CD44 and CD24 in primary tumour and after chemothe-
rapy in different groups of patients with BC.
PREDICTIVE AND PROGNOSTIC 
POTENTIAL OF CD44 
AND CD24 EXPRESSION 
IN PRIMARY TUMOUR AND AFTER 
CHEMOTHERAPY IN PATIENTS 
WITH BREAST CANCER
Aim: to evaluate prognostic and predictive value of surface-cells markers — CD44 
and CD24 in the primary tumour tissue and after neoadjuvant chemotherapy (NACT) 
in different groups of patients of breast cancer (BC). Object and methods: specimens 
of the primary tumour and specimens after chemotherapy in 106 patients with invasive 
BC. The observed patients were treated at the Natio nal Cancer Institute. Immuno-
histochemical staining for CD44 and CD24 was performed in tumour specimens. The 
survival analysis was performed depending on the clinical and pathological data and 
the expression of markers CD44, CD24, CD44+/CD24−, CD44+/CD24+. Results: 
different expressions of markers in the primary tumour tissue and after NACT were 
detected. An increase of the expression of CD44+ and CD44+/CD24− has been not-
ed in tumour tissue after NACT, which may play a role in the development of che-
moresistance and the possible mechanism of relapse of invasive BC. The prognos-
tic value of triple negative subtype of ВС, tumour size, coexpression of noninvasive 
CD44+/CD24+ cells was revealed in the Cox regression model. Conclusion: the differ-
ing expression of surface-cells markers in the primary tumour and after NACT may 
reflect intratumoral heterogeneity of the BC and the possible development of che-
moresistance. Triple negative subtype and tumour size were revealed as the risk fac-
tors associated with survival. Markers CD44 and CD24 were insufficient factors to 
determine the prognosis.
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MATERIALS AND METHODS
Specimens of the primary tumour and specimens af-
ter chemotherapy in patients with invasive BC have been 
studied separately. The observed patients were treated at 
the National Cancer Institute from 2008 to 2013.
The criteria for inclusion in this research were the fol-
lowing: women samples; histologically confirmed BC; 
tumour samples available for study. The medical records, 
pathology reports of the patients for obtaining clinical in-
formation were analyzed. The disease stage was classi-
fied according to the TNM AJCC categories (6th edition). 
A local ethical committee approved the study protocol.
From 130 cases of BC included in this research spec-
imens only 106 patients were suitable for staining and in-
formative for immunohistochemical (IHC) results. Pa-
tients were divided into two groups: group 0 — the patients 
with directly examined the primary tumour; group 1 — 
the patients after neoadjuvant chemotherapy (NACT). 
The median of observation was 48.5 months (interquar-
tile range Q1 = 36.5 months, Q3 = 63.5 months).
Clinical and pathological characteristics of patients 
are indicated in Table 1. NACT was conducted mainly 
to patients up to 50 years old (the difference between the 
groups by age is statistically significant, p = 0.02). The 
median age for group 0 was 52.5 years old, for group 1 — 
47 years old.
The distribution of disease stages according to T and 
N categories between the groups was different (p < 0.05). 
It was caused by NACT criterion for grouping. Among 
the patients having operative treatment immediately, 
82.5% of them had early stages of BC, and 19.2% of the 
patients had the IIIA stage. It is due to staging of dis-
ease after surgery considering the regional lymph node 
involvement. NACT was performed for the majority 
of patients (66.7%) with the locally advanced BC in ac-
cordance with standard treatment protocols. Regimens 
of NACT included mainly anthracyclines (90.7%) and 
paclitaxel were used in 9.3% of cases. The distribution 
of tumour phenotype did not reveal a statistically signi-
ficant difference between the groups (p = 0.75). The ma-
jority of patients were patients with luminal tumour sub-
types in both groups.
IHC analysis. The original hematoxylin-eosin-stained 
patients’ glasses in the retrospective sample were exam-
ined and noted by the pathomorphologist for further 
analysis of cell surface markers. Specific primary anti-
CD44 antibodies (polyclonal rabbit antibodies, 1:100, 
Thermo Scientific, USA) and CD24 (SN3, monoclo-
nal mouse antibodies, 1:200, Thermo Scientific, USA) 
were used for IHC staining according to the methodolo-
gy described in previous research [23]. Two pathologists 
who weren’t aware the clinical outcomes of patients in-
dependently carried out assessment of staining results. 
IHC surrogate panel (ER, PgR, HER2) was used to de-
termine the subtypes of BC [24].
Statistical analysis. DFS was defined as a period from 
the date of operations to the documented date of recur-
rence and/or distant metastases. Overall survival was de-
fined as a number of months from the diagnosis to the date 
of death. Censored overall survival was taken into account 
when the date of death of a patient was unknown and the 
date of the last observation was the indication point. Dif-
ferences in the frequencies of the main clinical-patho-
logical parameters and subtypes were analyzed using the 
chi-square test. Survival curves were constructed using 
the Kaplan — Meier method and ranking test was used to 
compare the meaning of survival rates by subtypes. Cox 
model was used for multivariate analysis in order to pre-
dict the survival relationship with patient age, tumour size, 
lymph node involvement, various subtypes of BC, NACT 
and cell-surface marker content. Hazard ratio (HR) and 
its 95% confidence interval (CI) were calculated to assess 
the degree of relationship.
Table 1
Clinical and pathological characteristic of patients in groups
Characteristics
Absolute value (%)
pGroup 0  
(n = 52)
Group 1 
(n = 54)
Age (Х ± SD), years old 50.6 ± 10.5 46.2 ± 9.4 0.02
Age range, years 27–71 28–64
Median, years 52.5 47
25–75 quartiles, years 42.5–58.5 30–55
Stage
(AJCC)
I 4 (7.7) 0
< 0.001
IIA 20 (38.5) 6 (11.1)
IIB 18 (34.6) 22 (40.7)
IIIA 10 (19.2) 25 (46.3)
IIIB 0 (0.0) 1 (1.9)
Category  
T
1 6 (11.5) 2 (3.7)
0.002
2 46 (88.5) 40 (74.1)
3 0 (0.0) 10 (18.5)
4 0 (0.0) 2 (3.7)
Category  
N
0 22 (42.3) 9 (16.7)
0.0081 20 (38.5) 24 (44.4)
2 10 (19.2) 21 (38.9)
Subtype Luminal А 19 (36.5) 17 (31.5)
0.75
Luminal В (HER2–) 18 (34.6) 19 (35.2)
Luminal В (HER2+) 1 (1.9) 4 (7.4)
Triple negative BC (TNBC) 12 (23.1) 12 (22.2)
HER2/neu expression 2 (3.9) 2 (3.7)
A critical level of significance was chosen at p < 0.05. 
The analysis was performed using statistical software 
packages MedCalc 17.9.2 (MedCalc Software bvba, 
1993–2017).
RESULTS AND COMMENTS
Analysis of expression of immunophenotypes CD44, 
CD24, CD44+/CD24–, CD44+/CD24+ in different groups 
of patients. IHC analysis of the expression of CD44, 
CD24, CD44+/CD24– as presumed CSC was per-
formed in 106 patients with an invasive BC in order to 
identify the association of these markers with the treat-
ment (Table 2).
There was no statistically significant difference for 
biomarker of the CD24 (p = 0.16) in the groups of pa-
tients with and without NACT. But there was a tendency 
(p = 0.08) to increase CD44+ expression in the tumour tis-
sue after NACT (59.3% of cases), as there was a predomi-
nant lack of CD44 expression (59.6% of cases) in the pri-
mary tumour tissue.
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Table 2
Association of immunophenotypes CD44, CD24, CD44+/CD24–, 
CD44+/CD24+ in groups
Marker Expression
Absolute value (%)
pGroup 0
(n = 52)
Group 1
(n = 54)
CD24 − 34 (65.4) 27 (50.0)
0.16
+ 18 (34.6) 27 (50.0)
CD44 − 31 (59.6) 22 (40.7)
0.08
+ 21 (40.4) 32 (59.3)
CD44+/CD24− − 40 (76.9) 32 (59.3)
0.08
+ 12 (23.1) 22 (40.7)
CD44+/CD24+ − 39 (75.0) 38 (70.4)
0.48
+ 9 (17.3) 7 (13.0)
++ 3 (5.8) 8 (14.8)
+++ 1 (1.9) 1 (1.8)
In the distribution of the CSC putative marker, such 
as CD44+/CD24–, there was also a tendency (p = 0.08) to 
increase the level for patients after NACT. The expression 
of this immunophenotype was detected in 40.7% of cases 
after NACT and in 23.1% of cases in the primary tumour.
The coexpression of CD44+/CD24+ in the observed 
groups was also analyzed (Table 2) and there was ap-
proximately uniform absence of markers coexpression 
in both groups (75.0 and 70.4% of cases). High expres-
sion (2+ and 3+) of CD44+/CD24+ was detected in the 
tumour tissue after NACT more often (16.6%) than in 
the primary tumour (7.07%). Despite of revealed shift 
of CD44+/CD24+ statistically significant difference be-
tween the different groups of patients was not detected 
(p = 0.48). Thus, the data obtained in the research show 
a tendency to increase the expression of CD44+ and 
CD44+/CD24− (p = 0.08) in tumour tissue of breast in 
patients after NACT.
Survival analysis depending on clinical and pathological 
data and status of markers CD44, CD24, CD44+/CD24−, 
CD44+/CD24+. Univariate and multivariate analysis 
were performed in order to identify risks factors associ-
ated with survival. Cox proportional hazards regression 
model was used. In this model the categorical variables 
were clinical pathological data and the expression of the 
following specific cell surface markers: CD44, CD24, 
CD44+/CD24−, CD44+/CD24+.
Cox regression model allowed estimating the influ-
ence of the following factor signs on the survival distri-
bution: CD24 and CD44 expression (negative or posi-
tive), CD44+/CD24−, CD44+/CD24+ (negative or posi-
tive), age, tumour size (pT1, pT2, pT3 and pT4), lymph 
node status (negative and positive), disease stages and 
subtypes of BC. The analysis of Cox univariate model 
(Table 3) identified that survival is associated with coex-
pression of CD44+/CD24+ (p = 0.06, HR = 1.73; 95% 
CI 0.98–3.06) and tumour phenotype. A worse prog-
nosis was for triple negative subtype of BC (p < 0.001, 
HR = 3.29; 95% CI 1.72–6.28) and HER2/neu expres-
sion subtype (p = 0.09, HR = 2.89; 95% CI 0.86–9.73).
Age, stage of disease, category T and N and NACT 
are not significant for survival in Cox univariate mod-
el. The differences in the expression of immunopheno-
types CD44, CD24, CD44+/CD24− also were not found 
(Table 3).
Table 3
Analysis Cox univariate model of survival prognosis  
depending on clinical and pathological data and expression  
of cell surface markers
Factor Index,b ± m p HR (95% CI)
Group 1 vs 0 0.06 ± 0.28 0.84 1.06 (0.61–1.84)
Age 0.000 ± 0.014 0.97 1.00 (0.97–1.03)
CD24+ vs CD24− –0.01 ± 0.28 0.98 0.99 (0.57–1.71)
CD44+ vs CD44− –0.02 ± 0.28 0.95 0.98 (0.57–1.70)
CD44+/CD24+ + vs – 0.55 ± 0.29 0.06 1.73 (0.98–3.06)
CD44+/CD24−
+ vs – –0.24 ± 0.30 0.44 0.79 (0.44–1.42)
ТNBC vs luminal 1.19 ± 0.33 <0.001 3.29 (1.72–6.28)
HER2(+) vs luminal 1.06 ± 0.62 0.09 2.89 (0.86–9.73)
Luminal В (HER2+) vs luminal 0.58 ± 0.51 0.34 1.79 (0.56–4.85)
Category T 0.20 ± 0.18 0.25 1.22 (0.86–1.74)
Category N – vs + –0.04 ± 0.30 0.89 0.96 (0.53–1.73)
Results of Cox univariate analysis can be presented 
graphically (Figure).
Figure. Cox univariate model for survival analysis
Multivariate analysis of survival. We also have consid-
ered applying multivariate forecasting model, while objec-
tive estimation of prediction seldom depends on one iso-
lated factor.
After the selection of significant features using the 
step-by-step inclusion/exclusion method (threshold 
of inclusion p < 0.2, exclusion threshold p > 0.4), a mul-
tivariate model of prognosis was constructed (Table 4).
Table 4
Cox multivariate model for survival analysis
Factor Index,b ± m p HR (95% CI)
ТNBC vs luminal 1.21 ± 0.33 < 0.001 3.4 (1.7–6.5)
HER2(+) vs luminal 0.99 ± 0.63 0.12 2.7 (0.8–9.3)
Luminal В (HER2+) vs luminal 0.45 ± 0.62 0.46 –
Category T 0.31 ± 0.19 0.10 1.4 (0.9–2.0)
CD44+/CD24+ + vs – 0.47 ± 0.30 0.12 1.6 (0.9–2.9)
In the multivariate model, TN subtype of BC was the 
only significant prognostic variable which influenced on 
survival (p < 0.001, HR = 3.4; 95% CI 1.7–6.5). Neverthe-
less, the factors that influence on survival indirectly were 
also HER2/neu expression subtype (p = 0.12, HR = 2.7; 
95% CI 0.8–9.3), luminal B (HER2+) positive subtype 
(p = 0.46), coexpression of CD44+/CD24+ (p = 0.12, 
HR = 1.6; 95% CI 0.9–2.9) and category T. It was re-
vealed that the increase in tumour size resulted deterio-
ration of survival (p = 0.12; HR = 1.6; 95% CI 0.9–2.09).
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In the research we show that clinical and morpho-
logical features of patients of BC are different in groups 
having operative treatment immediately or NACT before 
surgery. It is known that chemotherapy has the selectivity 
for proliferating cells and how much chemotherapy acts 
on the clone of stem cells capable to be predictors of drug 
resistance and poor prognosis is still being studied [14].
We have found variable patterns of markers’ expres-
sion in different tumour samples. Our data are consistent 
with some previously observed trends — an increase of the 
number of CD44+ and CD44+/CD24− in tumour tissue af-
ter NACT [25]. We have noticed that CD44 was markedly 
expressed in tumour tissue of breast after NACT, which in-
dicates that CD44 is involved in tumorigenesis of BC. This 
result coincides with the data: CD44+ shows a more mes-
enchymal, mobile and less proliferative profile and is simi-
lar to stem cells [26]. An increase of CD44+ expression after 
chemotherapy may indicate the development of resistance 
to cytostatics [14, 27].
The same tendency in the expression of CD44+/CD24− 
tumour cells was noted in patients after NACT (p = 0.08). 
This shift of CD44+/CD24− was probably due to increase in 
the subpopulation of CD44+. The profile of CD44+/CD24− 
was previously widely investigated and their invasive nature 
was proved. It made this population possible CSC [9, 16]. 
The fact that a small population of CSC survives after che-
motherapy and causes the relapse of invasive BC [28] is still 
interesting for many researchers. It was stressed in some ar-
ticles that CD44+/CD24–/low cells demonstrate properties 
of CSC and chemoresistance [29] and CD24– cells enhance 
the resistance to doxorubicin [13]. The content of another 
cell surface marker, CD24, did not differ in tumour tissue 
of both groups in our research. Although the predictive sig-
nificance of CD24 cells after NACT in patients with BC was 
previously reported by other researchers [22], and in parti-
cular the stability of CD24–/low cells to the treatment of an-
thracyclines was mentioned [13].
Thus, analysis of cell surface markers expression re-
vealed the differences between groups with a tendency 
to a significant increase of CD44+ and CD44+/CD24− in 
tumour tissue of breast after NACT, which may play a cer-
tain role in the development of resistance to chemotherapy 
and in the possible mechanism of relapse after treatment.
We estimated the prognostic value of clinical-patholog-
ical indicators and cell surface markers CD24, CD44. We 
noticed that the TNBC showed a poor prognosis for sur-
vival, which corresponds to the previous investigations [30]. 
The trend towards a significant effect of the HER2/neu ex-
pression subtype on the survival in the univariate analysis 
has lost its significance in the Cox multivariate analysis. But 
the increase in tumour size resulted deterioration of surviv-
al in multivariate analysis.
In the Cox univariate and multivariate analysis we did 
not find any relationship between age, disease stage, lymph 
node involvement, NACT, CD44, CD24, CD44+/CD24− 
expression and clinical outcome — survival. Our data co-
incide with the research result [11] that there is no link be-
tween the status of CD44+/CD24− and survival.
However, according to other scientists’ investigations, 
CD44+/CD24− tumour cells were significantly associat-
ed with poor survival [10], CD24 expression was a marker 
of poor prognosis for the luminal A subtype [31]. It was also 
shown that negative CD24 tumours have a very low risk of tu-
mour progression, while CD24 positive tumours are associ-
ated with a short-term DFS [17]. Some researchers note that 
high expression of CD44 correlates with reduced DFS and 
the existence of distant metastases [13, 21, 32], other scien-
tists [22] — on the contrary, emphasize that CD44+ contrib-
utes to a favourable prognosis in patients with primary BC.
In our study, one of the prognostic factors was tumour 
cells with coexpression of CD44+/CD24+, which showed 
a tendency to a significant effect on survival in the uni-
variate analysis. Presented data show that non-invasive 
CD44+/CD24+ cells are plastic and can easily generate off-
spring of invasive CD44+/CD24− cells through activation 
of signalling Activin/Nodal [27]. The hypothesis of the 
variable existence of tumour cells, which are either CD44+ 
or CD24+, can reflect the current state of tumour with un-
dergoing constant cell renewal, differentiation and interac-
tion with the surrounding stroma [11]. It is permissible that 
CD44+ and CD24+ cells can undergo the independent clonal 
evolution [26] and thereby it emphasizes the biological hete-
rogeneity of BC.
CONCLUSION
Research results underline biological intratumoral 
heterogeneity of BC and demonstrate different expres-
sion of CD44, CD24 in tumour tissue of the primary BC 
and in samples after NACT. The investigated cell surface 
markers can undergo certain changes after NACT and, 
possibly, can increase resistance to the chemotherapy. 
CD44 and CD24 are markers associated with carcino-
genesis in BC, but in our research they were insufficient 
factors to determine the prognosis.
Further investigations are necessary to determine the 
place and role of CD24, CD44 in chemoresistance and 
prognosis of patients of BC.
REFERENCES
1. Eisemann N, Waldmann A, Katalinic A. Epidemiology of breast 
cancer — current figures and trends. Geburtshilfe Frauenheilkd 2013; 
73 (2): 130–5.
2. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mes-
enchymal transitions in development and disease. Cell 2009; 139 (5): 
871–90.
3. Bensimon J, Altmeyer-Morel S, Benjelloun H, et al. CD24(-/
low) stem-like breast cancer marker defines the radiation-resistant cells 
involved in memorization and transmission of radiation-induced ge-
nomic instability. Oncogene 2013; 32 (2): 251–8.
4. Dean M, Fojo T, Bates S. Tumour stem cells and drug resis-
tance. Nat Rev Cancer 2005; 5 (4): 275–84.
5. Baumann P, Cremers N, Kroese F, et al. CD24 expression 
causes the acquisition of multiple cellular properties associated with 
tumor growth and metastasis. Cancer Res 2005; 65 (23): 10783–93.
6. Blacking TM, Waterfall M, Argyle DJ. CD44 is associated with 
proliferation, rather than a specific cancer stem cell population, in cul-
tured canine cancer cells. Vet Immunol Immunopathol 2011; 141 (1–
2): 46–57.
7. Camerlingo R, Ferraro GA2, De Francesco F, et al. The role of 
CD44+/CD24−/low biomarker for screening, diagnosis and monitor-
ing of breast cancer. Oncol Rep 2014; 31 (3): 1127–32.
ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ
27ОНКОЛОГИЯ •  Т.  20 •  № 1 •  2018 27
8. Abraham BK, Fritz P, McClellan M, et al. Prevalence of 
CD44+/CD24-/low cells in breast cancer may not be associated with 
clinical outcome but may favor distant metastasis. Clin Cancer Res 
2005; 11 (3): 1154–9.
9. Sheridan C, Kishimoto H, Fuchs RK, et al. CD44+/CD24− 
breast cancer cells exhibit enhanced invasive properties: an early step 
necessary for metastasis. Breast Cancer Res 2006; 8 (5): R59.
10. Idowu MO, Kmieciak M, Dumur C, et al. CD44(+)/CD24(-/
low) cancer stem/progenitor cells are more abundant in triple-nega-
tive invasive breast carcinoma phenotype and are associated with poor 
outcome. Hum Pathol 2012; 43 (3): 364–73.
11. Honeth G, Bendahl PO, Ringnér M, et al. The CD44+/CD24− 
phenotype is enriched in basal-like breast tumors. Breast Cancer Res 
2008; 10 (3): R53.
12. Chekhun SV, Zadvorny TV, Tymovska YO, et al. СD44+/
CD24− markers of cancer stem cells in patients with breast cancer of 
different molecular subtypes. Exp Oncol 2015; 37 (1): 58–63.
13. Deng X, Apple S, Zhao H, et al. CD24 Expression and dif-
ferential resistance to chemotherapy in triple-negative breast cancer. 
Oncotarget 2017; 8 (24): 38294–308.
14. Yenigun VB, Ozpolat B, Kose GT. Response of CD44+/CD24− 
/low breast cancer stem/progenitor cells to tamoxifen- and doxorubi-
cin-induced autophagy. Int J Mol Med 2013; 31 (6): 1477–83.
15. Lee JH, Kim SH, Lee ES, Kim YS. CD24 overexpression in 
cancer development and progression: a meta-analysis. Oncol Rep 
2009; 22 (5): 1149–56.
16. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospec-
tive identification of tumorigenic breast cancer cells. Proc Natl Acad 
Sci USA 2003; 100 (7): 3983–8.
17. Kristiansen G, Winzer KJ, Mayordomo E, et al. CD24 expres-
sion is a new prognostic marker in breast cancer. Clin Cancer Res 
2003; 9 (13): 4906–13.
18. Kwon MJ, Han J, Seo JH, et al. CD24 overexpression is as-
sociated with poor prognosis in luminal a and triple-negative breast 
cancer. PLoS One 2015; 10 (10): e0139112.
19. Jang MH, Kang HJ, Jang KS, et al. Clinicopathological anal-
ysis of CD44 and CD24 expression in invasive breast cancer. Oncol 
Lett 2016; 12 (4): 2728–33.
20. Hosonaga M, Arima Y, Sugihara E, et al. Expression of 
CD24 is associated with HER2 expression and supports HER2-Akt 
signaling in HER2-positive breast cancer cells. Cancer Sci 2014; 105 
(7): 779–87.
21. Xu H, Wu K, Tian Y, et al. CD44 correlates with clinicopath-
ological characteristics and is upregulated by EGFR in breast cancer. 
Int J Oncol 2016; 49(4): 1343–50.
22. Horiguchi K, Toi M, Horiguchi S, et al. Predictive value of 
CD24 and CD44 for neoadjuvant chemotherapy response and prog-
nosis in primary breast cancer patients. J Med Dent Sci 2010; 57 (2): 
165–75.
23. Ryspayeva DE, Smolanka II, Dudnichenko АS, et al. Are 
CD44(+)/CD24(-) cells the assumed cancer stem cells in breast can-
cer? Exp Oncol 2017; 39 (3): 224–8.
24. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer 
subtypes, and survival in the Carolina Breast Cancer Study. JAMA 
2006; 295 (21): 2492–502.
25. Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumor-
igenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 
100 (9): 672–9.
26. Shipitsin M, Campbell LL, Argani P, et al. Molecular defini-
tion of breast tumor heterogeneity. Cancer Cell 2007; 11 (3): 259–73.
27. Meyer MJ, Fleming JM, Ali MA, et al. Dynamic regulation of 
CD24 and the invasive, CD44posCD24neg phenotype in breast can-
cer cell lines. Breast Cancer Res 2009; 11 (6): R82.
28. Fillmore CM, Kuperwasser C. Human breast cancer cell lines 
contain stem-like cells that self-renew, give rise to phenotypically diverse 
progeny and survive chemotherapy. Breast Cancer Res 2008; 10 (2): R25.
29. Ge G, Zhou C, Ren Y, et al. Enhanced SLC34A2 in breast can-
cer stem cell-like cells induces chemotherapeutic resistance to doxoru-
bicin via SLC34A2-Bmi1-ABCC5 signaling. Tumour Biol 2016; 37 
(4): 5049–62.
30. Choi YL, Oh E, Park S, et al. Triple-negative, basal-like, and 
quintuple-negative breast cancers: better prediction model for surviv-
al. BMC Cancer 2010; 10: 507.
31. de Mascarel I, Debled M, Brouste V, et al. Comprehensive 
prognostic analysis in breast cancer integrating clinical, tumoral, mi-
cro-environmental and immunohistochemical criteria. Springerplus 
2015; 4: 528.
32. McFarlane S, Coulter JA, Tibbits P, et al. CD44 increases 
the efficiency of distant metastasis of breast cancer. Oncotarget 2015; 
6 (13): 11465–76.
ПРЕДИКТИВНИЙ І ПРОГНОСТИЧНИЙ 
ПОТЕНЦІАЛ ЕКСПРЕСІЇ CD44 І CD24 
У ПЕРВИННІЙ ПУХЛИНІ ТА ПІСЛЯ 
ХІМІОТЕРАПІЇ У ПАЦІЄНТІВ З РАКОМ 
МОЛОЧНОЇ ЗАЛОЗИ
Д.Е. Риспаєва
Національний інститут раку МОЗ України,  
Київ, Україна
Резюме. Мета: оцінити прогностичне і предиктив-
не значення маркерів CD44 і CD24 у первинній пухли-
ні та після проведення неоад’ювантної хіміотерапії 
(НАХТ) у різних групах хворих на рак молочної зало-
зи (РМЗ). Об’єкт і методи: зразки тканини пухлин 
106 хворих на інвазивний РМЗ, які проходили лікуван-
ня в Національному інституті раку. Експресію мар-
керів CD44 і CD24 визначали за допомогою імуногіс-
тохімічного методу. Проведено аналіз виживаності 
пацієнтів залежно від клініко- патологічних даних і 
експресії CD44, CD24, CD44+/CD24−, CD44+/CD24+. 
Результати: виявлено відмінності в експресії дослі-
джуваних маркерів у первинній пухлинній тканині та 
після проведення НАХТ. Підвищення експресії CD44+ 
і CD44+/CD24– у пухлинній тканині після проведен-
ня НАХТ може відігравати певну роль у формуванні 
хіміо резистентності та можливому механізмі роз-
витку рецидиву інвазивного РМЗ. За допомогою ре-
гресивної моделі Кокса виявлено прогностичне зна-
чення тричі негативного підтипу РМЗ, розміру пух-
лини, коекспресії неінвазивних клітин CD44+/CD24+. 
Висновок: відмінність експресії поверхневих клітин-
них маркерів у первинній пухлині та після проведен-
ня НАХТ відображає внутрішньопухлинну гетероген-
ність РМЗ та, можливо, ймовірність розвитку хімі-
орезистентності. Прогностичними факторами, які 
пов’язані з виживаністю, виявилися тричі негатив-
ний підтип та розмір пухлини. Рівні експресії марке-
рів CD44 і CD24 виявилися недостатніми фактора-
ми для визначення прогнозу.
Ключові слова: рак молочної залози, стовбурові 
пухлинні клітини, CD44, CD24, виживаність, 
хіміотерапія, прогностичне значення.
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